Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose esketamine for postoperative depression after single-port laparoscopic hysterectomy
ChiCTR2500103453Phase 4Completed
- Sponsor
- Xinxiang Central Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in major depressive disorder (MDD) and anxiety disorder (2 arms), sponsored by Xinxiang Central Hospital. Primary endpoint: HADS depression score at 6 months after surgery. Started May 2025; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on ChiCTR2500103453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103453.